Back to top

messenger-rna: Archive

Zacks Equity Research

Novavax Stock Falls After FDA Puts Two Vaccine Programs on Hold

NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the combo shot reported nerve damage.

SNYNegative Net Change PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change

Sundeep Ganoria

Moderna Stock Falls 20% in a Month: Time to Sell or Hold?

Shares of MRNA have been declining after it lowered its long-term financial guidance. It has also pushed its breakeven point by another two years to 2028.

GSKPositive Net Change PFENegative Net Change MRNANegative Net Change

Zacks Equity Research

Here's Why You Should Retain Merit Medical Stock in Your Portfolio

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

DGXNegative Net Change UHSPositive Net Change BAXNegative Net Change MMSIPositive Net Change

Zacks Equity Research

MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.

SNYNegative Net Change GSKPositive Net Change MRKPositive Net Change MRNANegative Net Change

Zacks Equity Research

Novavax Stock Up 9% on FDA Nod for Updated COVID-19 Vaccine

The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.

SNYNegative Net Change PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change